Compare DNUT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | RCKT |
|---|---|---|
| Founded | 1937 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.4M | 428.6M |
| IPO Year | 2021 | N/A |
| Metric | DNUT | RCKT |
|---|---|---|
| Price | $3.39 | $3.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $6.22 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 2.3M | 2.2M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,534,272,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.50 | $2.19 |
| 52 Week High | $9.56 | $11.45 |
| Indicator | DNUT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 54.05 |
| Support Level | $4.12 | $3.43 |
| Resistance Level | $4.49 | $3.96 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 2.14 | 46.77 |
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.